Publications

Pharmacological research

Daraxonrasib (RMC-6236) pharmacokinetics: impact of transporters and drug-metabolizing enzymes on a first-in-class pan-RAS molecular glue.

01-07-2026

JCO precision oncology

Pharmacokinetics of 5-Fluorouracil in Patients Treated With Capecitabine Carrying the c.1236G>A DPYD Variant Allele.

01-06-2026

Clinical pharmacology and therapeutics

Reducing the Burden of Interaction Studies in Cancer Patients Using a Stable Isotopically Labeled Microtracer: A Proof-of-Concept Study with Alectinib.

01-03-2026

Cellular oncology (Dordrecht, Netherlands)

Disconnect between in vitro and in vivo efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma.

16-02-2026

Biomedical chromatography : BMC

An Overview of Liquid Chromatography-Mass Spectrometry (LC-MS) Methods for the Quantification of Antibody-Drug Conjugates.

01-02-2026

Journal of pharmaceutical and biomedical analysis

LC-MS/MS method development and validation for novel targeted anticancer therapies adagrasib, capmatinib, ensartinib, entrectinib, larotrectinib, lorlatinib, pralsetinib, selpercatinib and sotorasib.

15-12-2025

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Prolonged in-use physicochemical and biological stability of nivolumab and pembrolizumab diluted in saline infusion bags and in partially used medication vials.

01-12-2025

Therapeutic drug monitoring

Stabilization of Abiraterone in Human Plasma Using the Esterase Inhibitor Bis(4-nitrophenyl) Phosphate.

01-10-2025

Therapeutic drug monitoring

Clinical Application of Volumetric Absorptive Microsampling for Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs.

01-10-2025

Biomedical chromatography : BMC

Validated LC-MS/MS Method for Quantifying the Antiparasitic Nitroimidazole DNDI-0690 in Preclinical Target Site PK/PD Studies.

01-08-2025

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Quantitative analysis of DNDI-6174 using UPLC-MS/MS: A preclinical target site pharmacokinetic study.

01-08-2025

Acta pharmaceutica Sinica. B

Resistance mutations and the blood-brain barrier: Key challenges in targeted treatment of brain metastatic non-small cell lung cancer.

01-08-2025

European journal of cancer (Oxford, England : 1990)

Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study.

25-06-2025

Biomedical chromatography : BMC

Development and Validation of a Rapid and Simple LC-MS/MS Method for Quantification of the Anti-Microtubule, Anti-Cancer Agent ABT-751 in Human and Mouse Plasma and Mouse Tissues.

01-06-2025

Oncology and therapy

Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors.

01-06-2025

Biomedical chromatography : BMC

Advancing Therapeutic Drug Monitoring for Oral Targeted Anticancer Drugs: From Hospital-Based Towards Home-Sampling.

01-05-2025

Acta pharmacologica Sinica

Intestinal human carboxylesterase 2 (CES2) expression rescues drug metabolism and most metabolic syndrome phenotypes in global Ces2 cluster knockout mice.

01-03-2025

Drug discovery today

The feasibility of using real world data as external control arms in oncology trials.

01-03-2025

Transplantation and cellular therapy

Defining the Quality Attributes for Tumor-Infiltrating Lymphocyte Medicinal Products.

01-03-2025

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

An ultra-sensitive liquid chromatography tandem mass spectrometry method for the simultaneous quantification of ²H₆-alectinib and alectinib in human plasma to support a microtracer food-effect trial.

01-03-2025

Breast cancer research and treatment

Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort.

01-02-2025

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices.

01-01-2025

Clinical pharmacokinetics

A Population Pharmacokinetic Study to Evaluate Doxorubicin Exposure Across All Age Groups.

01-12-2024

PloS one

Platinum retention in plasma, urine, and normal colonic mucosa in cisplatin-treated testicular cancer survivors.

14-11-2024

Drug metabolism and disposition: the biological fate of chemicals

Early Prediction and Impact Assessment of CYP3A4-Related Drug-Drug Interactions for Small-Molecule Anticancer Drugs Using Human-CYP3A4-Transgenic Mouse Models.

16-10-2024

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Development and validation of an LC-MS/MS method for simultaneous quantification of eight drugs in plasma and brain: Application in a pharmacokinetic study in mice.

15-10-2024

Molecular pharmaceutics

Brain Exposure to the Macrocyclic ALK Inhibitor Zotizalkib is Restricted by ABCB1, and Its Plasma Disposition is Affected by Mouse Carboxylesterase 1c.

07-10-2024

Toxicology and applied pharmacology

The role of drug efflux and uptake transporters in the plasma pharmacokinetics and tissue disposition of morphine and its main metabolites.

01-09-2024

Cancer chemotherapy and pharmacology

A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure-response relationships: a proof-of-concept study with alectinib.

01-09-2024

ESMO real world data and digital oncology

Clinical text mining of the performance status and progression-free survival to facilitate data collection in cancer research: an exploratory study.

01-09-2024

Fluids and barriers of the CNS

ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brain.

05-08-2024

Journal of pharmaceutical and biomedical analysis

ELISA assay for the quantification of ipilimumab in human serum, plasma, milk, and cerebrospinal fluid.

01-08-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

01-08-2024

Journal of pharmaceutical and biomedical analysis

Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of the antimalarial drug pyronaridine in human whole blood.

01-08-2024

Therapeutic drug monitoring

Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites.

01-08-2024

Cancer chemotherapy and pharmacology

Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment.

01-07-2024

European journal of drug metabolism and pharmacokinetics

The Use of Microdosing for In vivo Phenotyping of Cytochrome P450 Enzymes: Where Do We Stand? A Narrative Review.

01-07-2024

The Journal of antimicrobial chemotherapy

Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia.

01-07-2024

Journal of pharmaceutical and biomedical analysis

A multiplex UPLC-MS/MS method for the quantification of three PD-L1 checkpoint inhibitors, atezolizumab, avelumab, and durvalumab, in human serum.

15-06-2024

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

ABCB1 attenuates brain exposure to the KRAS^G12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure.

01-06-2024

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugs.

01-06-2024

Cancer medicine

Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune-related adverse events of immune checkpoint inhibitors.

01-06-2024

Oncology research and treatment

Intradermal Naked DNA Vaccination by DNA Tattooing for Mounting Tumor-Specific Immunity in Stage IV Melanoma Patients: A Phase I Clinical Trial.

08-04-2024

Molecular pharmaceutics

Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in Mice.

01-04-2024

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Redispensing of expensive oral anticancer medicines: A practical application.

01-04-2024

Toxicology and applied pharmacology

The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib.

01-04-2024

Cancer drug resistance (Alhambra, Calif.)

Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel.

06-02-2024

Cancer chemotherapy and pharmacology

Are novel oral oncolytics underdosed in obese patients?

01-02-2024

Journal of clinical pharmacology

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.

01-02-2024

Therapeutic drug monitoring

Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients.

01-02-2024

Daraxonrasib (RMC-6236) pharmacokinetics: impact of transporters and drug-metabolizing enzymes on a first-in-class pan-RAS molecular glue.

Pharmacokinetics of 5-Fluorouracil in Patients Treated With Capecitabine Carrying the c.1236G>A DPYD Variant Allele.

Reducing the Burden of Interaction Studies in Cancer Patients Using a Stable Isotopically Labeled Microtracer: A Proof-of-Concept Study with Alectinib.

Disconnect between in vitro and in vivo efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma.

An Overview of Liquid Chromatography-Mass Spectrometry (LC-MS) Methods for the Quantification of Antibody-Drug Conjugates.

LC-MS/MS method development and validation for novel targeted anticancer therapies adagrasib, capmatinib, ensartinib, entrectinib, larotrectinib, lorlatinib, pralsetinib, selpercatinib and sotorasib.

Prolonged in-use physicochemical and biological stability of nivolumab and pembrolizumab diluted in saline infusion bags and in partially used medication vials.

Stabilization of Abiraterone in Human Plasma Using the Esterase Inhibitor Bis(4-nitrophenyl) Phosphate.

Clinical Application of Volumetric Absorptive Microsampling for Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs.

Validated LC-MS/MS Method for Quantifying the Antiparasitic Nitroimidazole DNDI-0690 in Preclinical Target Site PK/PD Studies.

Quantitative analysis of DNDI-6174 using UPLC-MS/MS: A preclinical target site pharmacokinetic study.

Resistance mutations and the blood-brain barrier: Key challenges in targeted treatment of brain metastatic non-small cell lung cancer.

Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study.

Development and Validation of a Rapid and Simple LC-MS/MS Method for Quantification of the Anti-Microtubule, Anti-Cancer Agent ABT-751 in Human and Mouse Plasma and Mouse Tissues.

Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors.

Advancing Therapeutic Drug Monitoring for Oral Targeted Anticancer Drugs: From Hospital-Based Towards Home-Sampling.

Intestinal human carboxylesterase 2 (CES2) expression rescues drug metabolism and most metabolic syndrome phenotypes in global Ces2 cluster knockout mice.

The feasibility of using real world data as external control arms in oncology trials.

Defining the Quality Attributes for Tumor-Infiltrating Lymphocyte Medicinal Products.

An ultra-sensitive liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 2H6-alectinib and alectinib in human plasma to support a microtracer food-effect trial.

Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort.

Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices.

A Population Pharmacokinetic Study to Evaluate Doxorubicin Exposure Across All Age Groups.

Platinum retention in plasma, urine, and normal colonic mucosa in cisplatin-treated testicular cancer survivors.

Early Prediction and Impact Assessment of CYP3A4-Related Drug-Drug Interactions for Small-Molecule Anticancer Drugs Using Human-CYP3A4-Transgenic Mouse Models.

Development and validation of an LC-MS/MS method for simultaneous quantification of eight drugs in plasma and brain: Application in a pharmacokinetic study in mice.

Brain Exposure to the Macrocyclic ALK Inhibitor Zotizalkib is Restricted by ABCB1, and Its Plasma Disposition is Affected by Mouse Carboxylesterase 1c.

The role of drug efflux and uptake transporters in the plasma pharmacokinetics and tissue disposition of morphine and its main metabolites.

A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure-response relationships: a proof-of-concept study with alectinib.

Clinical text mining of the performance status and progression-free survival to facilitate data collection in cancer research: an exploratory study.

ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brain.

ELISA assay for the quantification of ipilimumab in human serum, plasma, milk, and cerebrospinal fluid.

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of the antimalarial drug pyronaridine in human whole blood.

Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites.

Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment.

The Use of Microdosing for In vivo Phenotyping of Cytochrome P450 Enzymes: Where Do We Stand? A Narrative Review.

Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia.

A multiplex UPLC-MS/MS method for the quantification of three PD-L1 checkpoint inhibitors, atezolizumab, avelumab, and durvalumab, in human serum.

ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure.

Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugs.

Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune-related adverse events of immune checkpoint inhibitors.

Intradermal Naked DNA Vaccination by DNA Tattooing for Mounting Tumor-Specific Immunity in Stage IV Melanoma Patients: A Phase I Clinical Trial.

Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in Mice.

Redispensing of expensive oral anticancer medicines: A practical application.

The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib.

Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel.

Are novel oral oncolytics underdosed in obese patients?

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.

Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients.

This site uses cookies

An ultra-sensitive liquid chromatography tandem mass spectrometry method for the simultaneous quantification of ²H₆-alectinib and alectinib in human plasma to support a microtracer food-effect trial.

ABCB1 attenuates brain exposure to the KRAS^G12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure.